STADA Arzneimittel
Privately held: no public share price
Assets
(6 total)
6Total Assets
3Approved
2Phase 3 / Filed
1Phase 1–2 / Early
8Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
BAT1806(Tofidence) | Approved | IL-6 receptorMonoclonal antibody | Rheumatoid ArthritisCOVID-19 |
Budesonide (targeted-release)(TARPEYO / Nefecon) | Approved | Glucocorticoid receptorSmall molecule | IgA Nephropathy |
| Approved | IL-12 p40Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease | |
| Phase 3 | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration | |
Trigel(Lecigon) | Phase 3 | COMTSmall molecule | Parkinson's Disease |
| Preclinical / Unstaged | VEGF-AProtein / enzyme therapeutic | Age-Related Macular Degeneration |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
29 October 2026FDA action dateRanibizumab (Ximluci)BsUFA action date for the Ximluci ranibizumab biosimilar BLA (Xbrane)
US, FDA · Xbrane Biopharma; Valorum Biologics · Source ↗
3 June 2026Filing acceptedRanibizumab (Ximluci)FDA accepts the resubmitted BLA for the Ximluci ranibizumab biosimilar (Xbrane)
US, FDA · Xbrane Biopharma; Valorum Biologics · Source ↗
Financial reports
No financial reports recorded.